

Edgar Filing: GISH BIOMEDICAL INC - Form SC 13D/A

GISH BIOMEDICAL INC  
Form SC 13D/A  
March 20, 2003

-----  
OMB APPROVAL  
-----

OMB Number: 3235-0145  
Expires: October 31, 1994  
Estimated average burden  
hours per response...14.90  
-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(AMENDMENT NO. 5)

GISH BIOMEDICAL, INC.  
(NAME OF ISSUER)

COMMON STOCK, PAR VALUE \$.01 PER SHARE  
(TITLE OF CLASS OF SECURITIES)

376360103  
(CUSIP NUMBER)

S. CRAIG TOMPKINS, DIRECTOR OF BUSINESS AFFAIRS, READING INTERNATIONAL, INC.  
550 SOUTH HOPE STREET, SUITE 1825, LOS ANGELES, CALIFORNIA 90071 (213) 235-0540  
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED  
TO RECEIVE NOTICES AND COMMUNICATIONS)

MARCH 19, 2003  
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box.  
[ ]

NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Edgar Filing: GISH BIOMEDICAL INC - Form SC 13D/A

CUSIP NO. 376360103

PAGE 2 OF 4 PAGES

-----

1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Reading International, Inc.  
95-3885184

-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [X]

-----

3 SEC USE ONLY

-----

4 SOURCE OF FUNDS\*  
WC

-----

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS  
2 (d) or 2 (e) [ ]

-----

6 CITIZENSHIP OR PLACE OF ORGANIZATION  
Nevada

-----

	7	SOLE VOTING POWER	424,537
NUMBER OF SHARES			
BENEFICIALLY	8	SHARED VOTING POWER	-0-
OWNED BY EACH			
REPORTING	9	SOLE DISPOSITIVE POWER	424,537
PERSON WITH			
	10	SHARED DISPOSITIVE POWER	-0-

-----

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
424,537

-----

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\* [ ]

-----

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
11.8%

-----

14 TYPE OF REPORTING PERSON\*  
CO

-----

\*SEE INSTRUCTIONS BEFORE FILLING OUT.

SCHEDULE 13D

CUSIP NO. 376360103

PAGE 3 OF 4 PAGES

ITEM 1. SECURITY AND ISSUER.

This Amendment No. 5 relates to the Schedule 13D filed November 25, 1998 in connection with the ownership by Reading International, Inc. (formerly Citadel Holding Corporation) ("Reading") of the Common Stock, no par value (the "Common Stock"), of Gish Biomedical, Inc., a California corporation (the "Issuer") whose principal executive offices are located at 22942 Arroyo Vista, Rancho Santa Margarita, California 92688.

Edgar Filing: GISH BIOMEDICAL INC - Form SC 13D/A

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

Since the date of the last Schedule 13D/A filing of January 23, 2003, Reading has disposed of 106,163 Shares at the aggregate sale price of \$147,398.72 inclusive of brokerage commissions, where applicable. Reading has made a decision to over time liquidate its investment in Gish.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

a) To the best knowledge of Reading, the aggregate amount of securities held by the Reading is 424,537 shares of Common Stock, representing approximately 11.8% of the shares of Common Stock outstanding. The percentage ownership is based upon the total Shares outstanding of 3,592,145 reported in the Company's Form 10-Q for the period ended December 31, 2002.

b) All of the shares of Common Stock reported under this Item 5 with respect to Reading are held by Reading, and Reading has the sole power to vote and dispose of the 424,537 Shares in question.

c) Reading has engaged, within the last thirty days, in the following transactions in Common Stock of the Issuer, all of which were effectuated on the Nasdaq National Market.

DATE OF TRANSACTION	AMOUNT SOLD/SHARES	SALE PRICE
02-25-03	800	\$1.47
03-04-03	65,000	\$1.44
03-05-03	3,863	\$1.44
03-12-03	5,000	\$1.24
03-13-03	1,000	\$1.27
03-13-03	10,000	\$1.27
03-13-03	5,000	\$1.28
03-13-03	1,000	\$1.30
03-13-03	9,000	\$1.31
03-14-03	2,000	\$1.36
03-14-03	1,100	\$1.30
03-17-03	2,400	\$1.35
TOTAL	106,163 SHARES	

SCHEDULE 13D

CUSIP NO. 376360103

PAGE 4 OF 4 PAGES

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

None.

ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.

None.

SIGNATURE

Edgar Filing: GISH BIOMEDICAL INC - Form SC 13D/A

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 19, 2003

READING INTERNATIONAL, INC.  
a Nevada corporation

By: /s/ S. Craig Tompkins

-----  
S. Craig Tompkins  
Executive Vice President  
Director of Business Affairs